5Hotta N, Toyta T, Matsuoka K, Shingeta Y, Kikkawa R,Kaneko T, Takahashi A, Sugimura K, Koike Y, Ishii J,Sakamoto N. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy[J]. Diabetes Care, 2001; 24(10): 1
6Shy ME, Frohman EM, So YT, Arezzo JC, Cornblath DR,Giuliani MJ, Kincaid JC, Ochoa JL, Parry GJ, Weimer LH.Quantitative sensory testing. Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology [J]. Neurology,
7Diabetes Control and Complication Trial Research Group.The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in InsulinDependent Diabetes Mellitus [ J ]. N Engl J Med , 1993; 329(14): 977 -986
8D. Ziegler. The design of trials for treatment of diabetic neuropathy[J]. Neuropathy Res Commun, 1997 ; 21 ( 1 ): 83 -91
9Pfeifer MA, Schumer MP. Clinical trials of diabetic neuropathy: past, present and future[J]. Diabetes, 1995; 44(12) :1 355-1 361
10Dyck PJ, O' Brien PC. Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy[J]. Diabetes Care, 1989;12(9): 649 -652
